<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The Janus kinase-2 (JAK-2) V617F mutation has been recently reported in patients with <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>), which is believed to underlie growth factor hypersensitivity displayed by haematopoietic progenitors in these disorders </plain></SENT>
<SENT sid="1" pm="."><plain>However, its frequency has been rarely determined in Taiwanese patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The frequency of JAK2-V617F mutation in patients with <z:mp ids='MP_0002872'>polycythaemia</z:mp> vera, <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythaemia</z:e> and idiopathic <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (IMF) was determined in the DNA from the peripheral blood leucocytes of 108 patients by genomic polymerase chain reaction and restriction enzyme-based assay </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The JAK2-V617F mutation could be detected in 28 of 33 <z:mp ids='MP_0002872'>polycythaemia</z:mp> vera patients (85%), 29 of 49 essential <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">thrombocythaemia</z:e> patients (59%) and 2 of 6 IMF patients (33%), but was not detected in 11 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or another 10 with other haematological diseases </plain></SENT>
<SENT sid="4" pm="."><plain>The presence of the JAK2 mutation was associated with specific <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> disease subtypes (P = 0.007), longer disease duration (P = 0.005), <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> (P = 0.019), a higher white blood cell count (P = 0.002) and a higher <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> level (P = 0.036) </plain></SENT>
<SENT sid="5" pm="."><plain>However, the overall risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> or <z:mp ids='MP_0001914'>bleeding</z:mp> was not affected by the presence of the JAK2 mutation (32 vs 17%; P = 0.22) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: The JAK2-V617F mutation can be frequently detected in the Taiwanese patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> disorders and therefore should be incorporated into the initial evaluation of patients suspected of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> </plain></SENT>
</text></document>